Professional Summary
Education & Certifications
- Fellowship: Stanford University Hematology and Oncology Fellowship (2015) CA
- Residency: Stanford University Internal Medicine Residency (2012) CA
- Internship: Stanford University Internal Medicine Residency (2011) CA
-
- Board Certification: American Board of Internal Medicine, Medical Oncology (2017)
- Board Certification, Oncology, American Board of Internal Medicine (2017)
- Board Certification: American Board of Internal Medicine, Internal Medicine (2013)
- PhD, University of Michigan, Immunology (2010)
- Medical Education: University of Michigan Health System (2010) MI
Honors & Awards
- Dean's Postdoctoral Fellowship, Stanford University (2014)
- Distinction in Academics and Research, University of Michigan, Ann Arbor (2010)
- Fellow Award, Leukemia and Lymphoma Society (2014-)
-
- Membership, Alpha Omega Alpha (2009)
- Predoctoral Fellowship Award, National Science Foundation (2002)
- Wiliam Dodd Robinson Award, University of Michigan, Ann Arbor (2010)
- Young Investigator Award, Journal of Clinical Oncology, Conquer Cancer Foundation (2015)
Memberships
- Member, Research Advisory Council, Cutaneous Lymphoma Foundation (2019 - Present)
- Steering Committee, Chair, San Francisco Lymphoma Rounds, Lymphoma Research Foundation (2020 - Present)
- Board Member, International Society of Cutaneous Lymphomas (2020 - Present)
-
Publications
-
Tumor antigen discovery through translation of the cancer genome.
Khodadoust, M. S., & Alizadeh, A. A. (2014). Tumor antigen discovery through translation of the cancer genome. Immunologic Research, 58(2-3), 292–99. -
Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Xu, G., Quon, A., … Hoppe, R. T. (2015). Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. International Journal of Radiation Oncology, Biology, Physics, 92(1), 99–106. -
Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.
Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., … Gotlib, J. (2016). Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia, 30(4), 947–50. -
-
The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity
Kappes, F., Waldmann, T., Mathew, V., Yu, J., Zhang, L., Khodadoust, M. S., … Markovitz, D. M. (2011). The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. GENES & DEVELOPMENT, 25(7), 673–678. -
DEK expression in melanocytic lesions
Kappes, F., Khodadoust, M. S., Yu, L., Kim, D. S. L., Fullen, D. R., Markovitz, D. M., & Ma, L. (2011). DEK expression in melanocytic lesions. HUMAN PATHOLOGY, 42(7), 932–938. -
Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene
Khodadoust, M. S., Verhaegen, M., Kappes, F., Riveiro-Falkenbach, E., Cigudosa, J. C., Kim, D. S. L., … Soengas, M. S. (2009). Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene. CANCER RESEARCH, 69(16), 6405–6413. -
DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress
Kappes, F., Fahrer, J., Khodadoust, M. S., Tabbert, A., Strasser, C., Mor-Vaknin, N., … Ferrando-May, E. (2008). DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. MOLECULAR AND CELLULAR BIOLOGY, 28(10), 3245–3257. -
The DEK nuclear autoantigen is a secreted chemotactic factor
Mor-Vaknin, N., Punturieri, A., Sitwala, K., Faulkner, N., Legendre, M., Khodadoust, M. S., … Markovitz, D. M. (2006). The DEK nuclear autoantigen is a secreted chemotactic factor. MOLECULAR AND CELLULAR BIOLOGY, 26(24), 9484–9496. -
p300/CBP-associated factor drives DEK into interchromatin granule clusters
Cleary, J., Sitwala, K. V., Khodadoust, M. S., Kwok, R. P. S., Mor-Vaknin, N., Cebrat, M., … Markovitz, D. M. (2005). p300/CBP-associated factor drives DEK into interchromatin granule clusters. JOURNAL OF BIOLOGICAL CHEMISTRY, 280(36), 31760–31767. -
Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A. W., Chen, B., Swaminathan, K., … Alizadeh, A. A. (2017). Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. NATURE, 543(7647), 723-? -
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., … Diehn, M. (2017). Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery. -
Profiling Tumor Infiltrating Immune Cells with CIBERSORT.
Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M., & Alizadeh, A. A. (2018). Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods in Molecular Biology (Clifton, N.J.), 1711, 243–59. -
T-cell immunopeptidomes reveal cell subtype surface markers derived from intracellular proteins.
Olsson, N., Schultz, L. M., Zhang, L., Khodadoust, M. S., Narayan, R., Czerwinski, D. K., … Elias, J. E. (2018). T-cell immunopeptidomes reveal cell subtype surface markers derived from intracellular proteins. Proteomics. -
Transcript-indexed ATAC-seq for precision immune profiling.
Satpathy, A. T., Saligrama, N., Buenrostro, J. D., Wei, Y., Wu, B., Rubin, A. J., … Chang, H. Y. (2018). Transcript-indexed ATAC-seq for precision immune profiling. Nature Medicine. -
Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., … Levy, R. (2015). Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. BLOOD. AMER SOC HEMATOLOGY. -
Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN
Czerwinski, D. K., Long, S. R., Khodadoust, M., Frank, M. J., Chu, M. P., Okada, A., … Levy, R. (2015). Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN. BLOOD. AMER SOC HEMATOLOGY. -
Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.
Khodadoust, M. S., Chu, M. P., Czerwinski, D., McDonald, K., Long, S., Kohrt, H. E., … Levy, R. (2015). Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.
Kurtz, D. M., Scherer, F., Green, M. R., Khodadoust, M. S., Klass, D. M., Zhou, L., … Alizadeh, A. A. (2015). Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC
Schultz, L. M., Olsson, N., Khodadoust, M., Narayan, R., Sagiv-Barfi, I., Elias, J., & Levy, R. (2015). T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC. BLOOD. AMER SOC HEMATOLOGY. -
Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.
Dai, J., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S., Weng, W.-K. K., & Kim, Y. H. (2018). Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome. JAMA Dermatology. -
Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era.
Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Advani, R. H., & Hoppe, R. T. (2014). Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Prognostic Factors, Treatment, and Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era
Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Advani, R. H., & Hoppe, R. T. (2014). Prognostic Factors, Treatment, and Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst.
Erdrich, J., Schaberg, K., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., … Beausang, J. F. (2018). Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Cold Spring Harbor Molecular Case Studies. -
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018785246. -
Pembrolizumab in mycosis fungoides and Sezary syndrome: Updated results of the CITN multicenter Phase 2 study
Khodadoust, M. S., Rook, A. H., Porcu, P., Foss, F., Moskowitz, A., Shustov, A. R., … Kim, Y. H. (2018). Pembrolizumab in mycosis fungoides and Sezary syndrome: Updated results of the CITN multicenter Phase 2 study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study
Bagot, M., Porcu, P., William, B., Vermeer, M., Whittaker, S., Wolff, C. R., … Kim, Y. (2018). IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study. EUROPEAN JOURNAL OF CANCER, 101, S29. -
Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens
Khodadoust, M., Olsson, N., Wagar, L., Chen, B., Rawson, K., Liu, C. L., … Alizadeh, A. A. (2016). Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens. BLOOD. AMER SOC HEMATOLOGY. -
Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome.
Torrey, H., Khodadoust, M., Tran, L., Baum, D., Defusco, A., Kim, Y. H., & Faustman, D. L. (2018). Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome. Leukemia. -
B cell lymphomas present immunoglobulin neoantigens.
Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B., Shree, T., Liu, C. L., … Alizadeh, A. A. (2018). B cell lymphomas present immunoglobulin neoantigens. Blood. -
Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.
Jin, M. C., Kurtz, D. M., Esfahani, M. S., Scherer, F., Craig, A. F. M., Soo, J., … Alizadeh, A. A. (2017). Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies
Torrey, H., Defusco, A., Baum, D., Rhabar, Z., Khodadoust, M., Kim, Y. H., & Faustman, D. L. (2018). Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies. CANCER IMMUNOLOGY RESEARCH, 6(9). -
Reply to J. Wang et al.
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2019). Reply to J. Wang et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801907. -
Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Final Results from a Phase 2 Multicenter Study
Khodadoust, M. S., Rook, A., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., … Kim, Y. H. (2018). Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Final Results from a Phase 2 Multicenter Study. BLOOD. AMER SOC HEMATOLOGY. -
The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Horwitz, S. M., Feldman, T. A., Hess, B. T., Khodadoust, M. S., Kim, Y. H., Munoz, J., … Hamlin, P. A. (2018). The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial
Bagot, M., Porcu, P., William, B. M., Battistella, M., Vermeer, M., Whittaker, S., … Kim, Y. H. (2018). IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial. BLOOD, 132. -
The Combination of Duvelisib, a PI3K-delta,gamma Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts
Horwitz, S. M., Moskowitz, A. J., Jacobsen, E. D., Mehta-Shah, N., Khodadoust, M. S., Fisher, D. C., … Weinstock, D. M. (2018). The Combination of Duvelisib, a PI3K-delta,gamma Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts. BLOOD. AMER SOC HEMATOLOGY. -
Volumetric modulated arc therapy and 3-dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs.
Obeid, J.-P., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., … Hiniker, S. M. (2019). Volumetric modulated arc therapy and 3-dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs. Practical Radiation Oncology. -
A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)
Kim, Y. H., Hoppe, R. T., Rook, A. H., Maity, A., Geskin, L. J., Horowitz, D. P., … Basile, L. A. (2016). A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT). BLOOD. AMER SOC HEMATOLOGY. -
Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies
Torrey, H., Defusco, A., Baum, D., Rahbar, Z., Khodadoust, M., Kim, Y. H., & Faustman, D. (2017). Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC. -
First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results
Bagot, M., Porcu, P., Ram-Wolff, C., Khodadoust, M., Battistella, M., Marie-Cardine, A., … Kim, Y. (2016). First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. BLOOD. AMER SOC HEMATOLOGY. -
Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study
Khodadoust, M., Rook, A. H., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., … Kim, Y. (2016). Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study. BLOOD. AMER SOC HEMATOLOGY. -
On the hunt for cancer neoantigens: is mass spectrometry the solution?
Elias, J., Olsson, N., Khodadoust, M., Wagar, L., Swaminathan, K., Green, M. R., … Alizadeh, A. A. (2017). On the hunt for cancer neoantigens: is mass spectrometry the solution? MOLECULAR & CELLULAR PROTEOMICS. AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC. -
SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial
Levy, R., Reagan, P. M., Friedberg, J. W., Bartlett, N. L., Gordon, L. I., Leung, A., … Chu, M. (2016). SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial. BLOOD. AMER SOC HEMATOLOGY. -
Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cyotmetry in Previously Untreated Patients
Czerwinski, D. K., Long, S. R., Khodadoust, M., Frank, M. J., Kardosh, A., Okada, A., … Levy, R. (2016). Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cyotmetry in Previously Untreated Patients. BLOOD. AMER SOC HEMATOLOGY. -
Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2019). Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply. JOURNAL OF CLINICAL ONCOLOGY, 37(9), 755-+. -
Determining cell type abundance and expression from bulk tissues with digital cytometry.
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., … Alizadeh, A. A. (2019). Determining cell type abundance and expression from bulk tissues with digital cytometry. Nature Biotechnology. -
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 36(28), 2845-+. -
B-cell lymphomas present immunoglobulin neoantigens
Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B., Shree, T., Liu, C. L., … Alizadeh, A. A. (2019). B-cell lymphomas present immunoglobulin neoantigens. BLOOD, 133(8), 878–81. -
Low-dose Total Skin Electron Beam Therapy for Refractory Cutaneous CD30 Positive Lymphoproliferative Disorders.
Panjwani, N., Yoo, C. H., Wang, E., Khodadoust, M. S., Kim, Y. H., Hoppe, R. T., & Hiniker, S. M. (2019). Low-dose Total Skin Electron Beam Therapy for Refractory Cutaneous CD30 Positive Lymphoproliferative Disorders. The Journal of Dermatological Treatment, 1–5. -
TNFR2-targeted elimination of Tregs and tumor-residing T cells in advanced cutaneous T cell lymphoma
Faustman, D. L., Torrey, H., Khodadoust, M., Defusco, A., Baum, D., Rahbar, Z., & Kim, Y. H. (2018). TNFR2-targeted elimination of Tregs and tumor-residing T cells in advanced cutaneous T cell lymphoma. CANCER RESEARCH, 78(13). -
Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Jin, M., Soo, J., Craig, A., Esfahani, M. S., … Alizadeh, A. A. (2017). Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Bagot, M., Porcu, P., Marie-Cardine, A., Battistella, M., William, B. M., Vermeer, M., … Kim, Y. H. (2019). IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. The Lancet. Oncology. -
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.
Narayan, R., Olsson, N., Wagar, L. E., Medeiros, B. C., Meyer, E., Czerwinski, D., … Levy, R. (2019). Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PloS One, 14(7), e0219547. -
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Khodadoust, M. S., Rook, A. H., Porcu, P., Foss, F., Moskowitz, A. J., Shustov, A., … Kim, Y. H. (2019). Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1901056. -
Predicting HLA class II antigen presentation through integrated deep learning.
Chen, B., Khodadoust, M. S., Olsson, N., Wagar, L. E., Fast, E., Liu, C. L., … Alizadeh, A. A. (2019). Predicting HLA class II antigen presentation through integrated deep learning. Nature Biotechnology. -
Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma
Shree, T., Khodadoust, M. S., Czerwinski, D., Frank, M. J., Hong, W. X., Greenstein, R., … Levy, R. (2019). Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor
Khodadoust, M., Kim, Y., Yang, M., Torrey, H., Tran, L., & Faustman, D. (2019). Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC. -
Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
Sworder, B., Kurtz, D. M., Macaulay, C., Frank, M. J., Alig, S., Garofalo, A., … Alizadeh, A. A. (2019). Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy. Blood. -
A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival.
Hoffmann, J. C., Atwater, S. K., Hong, E., Kumar, J., Khodadoust, M., Kim, Y., & Ohgami, R. S. (2020). A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival. The American Journal of Dermatopathology, 42(6), 389–96. -
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9). -
Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation
Kathuria, K. R., Chen, B., Khodadoust, M. S., Olsson, N., Davis, M. M., Elias, J. E., … Alizadeh, A. A. (2019). Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation. BLOOD. AMER SOC HEMATOLOGY. -
Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
Weng, W.-K. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., … Kim, Y. H. (2020). Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 4(18), 4474–82. -
Histopathologic Characterization of Mogamulizumab-associated Rash.
Wang, J. Y., Hirotsu, K. E., Neal, T. M., Raghavan, S. S., Kwong, B. Y., Khodadoust, M. S., … Rieger, K. E. (2020). Histopathologic Characterization of Mogamulizumab-associated Rash. The American Journal of Surgical Pathology. -
Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports.
Rojansky, R., Fernandez-Pol, S., Wang, E., Rieger, K. E., Novoa, R. A., Zehnder, J. L., … Brown, R. A. (2020). Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports. Diagnostic Pathology, 15(1), 122. -
Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2 Domain Mutations.
Fernandez-Pol, S., Petersen, B., Murphy, J.-E., Oak, J. S., Wang, E. B., Rieger, K. E., … Suarez, C. J. (2020). Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2 Domain Mutations. The American Journal of Surgical Pathology. -
A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Horwitz, S. M., Feldman, T. A., Hess, B. T., Khodadoust, M. S., Kim, Y. H., Munoz, J., … Hamlin, P. A. (2019). A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging
Schuerch, C. M., Phillips, D. J., Bhate, S. S., Barlow, G. L., Fling, S. P., Ramchurren, N., … Nolan, G. P. (2019). Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging. BLOOD. AMER SOC HEMATOLOGY. -
Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells
Ng, P. P., Mobasher, M., Yeung, K. S., Hotson, A. N., Hill, C. M., Madriaga, A., … Janc, J. W. (2019). Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells. BLOOD. AMER SOC HEMATOLOGY. -
A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
Mobasher, M., Miller, R. A., Janc, J. W., Kwei, L., Buggy, J. J., Luciano, G., … Radeski, D. (2019). A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment
Wagar, L. E., Sworder, B., Khodadoust, M. S., Davis, M. M., & Alizadeh, A. A. (2019). Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment. BLOOD. AMER SOC HEMATOLOGY. -
A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma
Shree, T., Khodadoust, M. S., Czerwinski, D. K., Frank, M. J., Hong, W. X., Greenstein, R., … Levy, R. (2019). A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Pembrolizumab in mycosis fungoides with PD-L1 structural variants.
Beygi, S., Fernandez-Pol, S., Duran, G., Wang, E. B., Stehr, H., Zehnder, J. L., … Khodadoust, M. S. (2021). Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Advances, 5(3), 771–74. -
Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma
Schurch, C. M., Phillips, D. J., Gutierrez, B. R., Matusiak, M., Bhate, S. S., Barlow, G. L., … Nolan, G. P. (2020). Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sezary Syndrome.
Fong, S., Hong, E. K., Khodadoust, M. S., Li, S., Hoppe, R. T., Kim, Y. H., & Hiniker, S. M. (2021). Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sezary Syndrome. Advances in Radiation Oncology, 6(3), 100629. -
Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome.
Hirotsu, K. E., Neal, T. M., Khodadoust, M. S., Wang, J. Y., Rieger, K. E., Strelo, J., … Kwong, B. Y. (2021). Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome. JAMA Dermatology. -
Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation.
Wu, Y. F., Skinner, L., Lewis, J., Khodadoust, M. S., Kim, Y. H., Kwong, B. Y., … Hiniker, S. M. (2021). Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation. Cancer Investigation, 1–11. -
Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging
Phillips, D., Schuerch, C. M., Khodadoust, M. S., Kim, Y. H., Nolan, G. P., & Jiang, S. (2021). Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging. FRONTIERS IN IMMUNOLOGY, 12, 687673. -
Maria: Accurate Prediction of MHC-II Peptide Presentation with Deep-Learning and Lymphoma Patient MHC-II Ligandome
Chen, B., Khodadoust, M., Olsson, N., Fast, E., Wagar, L. E., Liu, C. L., … Alizadeh, A. A. (2017). Maria: Accurate Prediction of MHC-II Peptide Presentation with Deep-Learning and Lymphoma Patient MHC-II Ligandome. BLOOD. AMER SOC HEMATOLOGY. -
Antigen presentation profiling reveals T-cell recognition of lymphoma imrnunoglobuhn neoantigens
Olsson, N., Khodadoust, M., Wagar, L., Swaminathan, K., Haabeth, O. A. W., Chen, B., … Elias, J. E. (2017). Antigen presentation profiling reveals T-cell recognition of lymphoma imrnunoglobuhn neoantigens. JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS. -
Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.
Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A. F. M., Khodadoust, M. S., Lovejoy, A. F., … Alizadeh, A. A. (2016). Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Primary Cytotoxic T Cell Lymphomas Harbor Recurrent Targetable Alterations in the JAK-STAT Pathway.
Lee, K., Evans, M. G., Yang, L., Ng, S., Snowden, C., Khodadoust, M. S., … Choi, J. (2021). Primary Cytotoxic T Cell Lymphomas Harbor Recurrent Targetable Alterations in the JAK-STAT Pathway. Blood. -
Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study.
Kim, Y. H., Khodadoust, M., de Masson, A., Moins-Teisserenc, H., Ito, T., Dwyer, K., … Bagot, M. (2021). Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study. European Journal of Cancer (Oxford, England : 1990), 156 Suppl 1, S48–S49. -
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.
Phillips, D., Matusiak, M., Gutierrez, B. R., Bhate, S. S., Barlow, G. L., Jiang, S., … Nolan, G. P. (2021). Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nature Communications, 12(1), 6726. -
Mechanisms of resistance to anti-CCR4 antibody, mogamulizumab, in cutaneous T cell lymphoma
Beygi, S., Fernandez-Pol, S., Duran, G., Wang, E. B., Kim, Y., & Khodadoust, M. (2021). Mechanisms of resistance to anti-CCR4 antibody, mogamulizumab, in cutaneous T cell lymphoma. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study
Kim, Y. H., Khodadoust, M., de Masson, A., Moins-Teisserenc, H., Ito, T., Dwyer, K., … Bagot, M. (2021). Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
Primary cytotoxic T cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway
Lee, K., Evans, M. G., Yang, L., Ng, S., Snowden, C., Khodadoust, M., … Choi, J. (2021). Primary cytotoxic T cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion.
Fernandez-Pol, S., Neishaboori, N., Chapman, C. M., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., & Suarez, C. J. (2021). Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion. JCO Precision Oncology, 5, 646–652. -
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., … Levy, R. (2022). CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity. Blood Cancer Discovery. -
Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma.
Beygi, S., Duran, G. E., Fernandez-Pol, S., Rook, A. H., Kim, Y. H., & Khodadoust, M. S. (2022). Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma. Blood. -
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.
Su, T., Duran, G. E., Kwang, A. C., Ramchurren, N., Fling, S. P., Kim, Y. H., & Khodadoust, M. S. (2022). Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome. Oncoimmunology, 11(1), 2115197. -
Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., … Levy, R. (2021). Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation
Shree, T., Haebe, S., Czerwinski, D. K., Day, G., Sathe, A., Khodadoust, M. S., … Levy, R. (2021). Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation. BLOOD. AMER SOC HEMATOLOGY. -
Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral TCell Lymphoma
Horwitz, S. M., Feldman, T. A., Ye, J. C., Khodadoust, M. S., Munoz, J., Hamlin, P. A., … Smith, S. M. (2021). Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral TCell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome.
Khodadoust, M. S., Mou, E., & Kim, Y. H. (2022). Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome. Blood. -
The DEK nuclear protein autoantigen is secreted chemotactic factor
Mor-Vaknin, N., Puntuieri, A., Sitwala, K., Faulkner, N., Legendre, M., Khodadoust, M. S., … Markovitz, D. M. (2006). The DEK nuclear protein autoantigen is secreted chemotactic factor. JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS. -
The nuclear protein DEK, a putative autoantigen in JRA, is secreted by activated human macrophages and exhibits chemokine activity.
Mor-Vaknin, N., Punturieri, A., Sitwala, K., Faulkner, N., Legendre, M., Cleary, J., … Markovitz, D. M. (2005). The nuclear protein DEK, a putative autoantigen in JRA, is secreted by activated human macrophages and exhibits chemokine activity. ARTHRITIS AND RHEUMATISM. WILEY-BLACKWELL. -
In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-delta,gamma Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma
Moskowitz, A. J., Koch, R., Mehta-Shah, N., Myskowski, P., Kheterpal, M., Dogan, A., … Horwitz, S. M. (2017). In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-delta,gamma Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial
Levy, R., Bartlett, N., Friedberg, J., Reagan, P., Gordon, L., Bergman, C., … Kohrt, H. (2016). SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Induction of apoptosis in lymphoid cell lines and primary CLL by HA14-1, a cell permeable organic small molecule that binds to the BH1 to BH3 surface pocket of Bcl-2 protein.
Hu, G. Y., Khodadoust, M., Konopleva, M., Huang, Z. W., & Andreeff, M. (2001). Induction of apoptosis in lymphoid cell lines and primary CLL by HA14-1, a cell permeable organic small molecule that binds to the BH1 to BH3 surface pocket of Bcl-2 protein. BLOOD. AMER SOC HEMATOLOGY. -
Bcl-2 antisense oligodeoxynucleotide (Genasense) enhances gemtuzumab ozogamicin (Mylotarg)-induced cytotoxicity in acute myeloid leukemia.
Khodadoust, M., Konopleva, M., Leysath, C., Frankel, Giles, F. J., & Andreeff, M. (2001). Bcl-2 antisense oligodeoxynucleotide (Genasense) enhances gemtuzumab ozogamicin (Mylotarg)-induced cytotoxicity in acute myeloid leukemia. BLOOD. AMER SOC HEMATOLOGY. -
Induction of apoptosis in primary human leukemia cells by HA14-1, a cell-permeable organic compound identified by protein structure-based computer screening that binds the BH1 to BH3 surface pocket of Bcl-2.
Andreeff, M., Konopleva, M., Leysath, C., Khodadoust, M., & Huang, Z. (2001). Induction of apoptosis in primary human leukemia cells by HA14-1, a cell-permeable organic compound identified by protein structure-based computer screening that binds the BH1 to BH3 surface pocket of Bcl-2. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Sworder, B. J., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N., Garofalo, A., … Alizadeh, A. A. (2022). Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. -
Hepatosplenic T-cell lymphoma with STAT5B and SETD2 mutations recurring as cells with NK-cell immunophenotype.
Khodadoust, M., & Silva, O. (2023). Hepatosplenic T-cell lymphoma with STAT5B and SETD2 mutations recurring as cells with NK-cell immunophenotype. Blood, 141(5), 555. -
Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
Shree, T., Haebe, S., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., … Levy, R. (2022). Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Minimal/measurable residual disease (MRD) monitoring in patients with lymphoid neoplasms by high-throughput sequencing of the T-cell receptor.
Tung, J. K., Jangam, D., Ho, C. C., Fung, E., Khodadoust, M. S., Kim, Y. H., … Zhang, B. M. (2023). Minimal/measurable residual disease (MRD) monitoring in patients with lymphoid neoplasms by high-throughput sequencing of the T-cell receptor. The Journal of Molecular Diagnostics : JMD. -
Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS
Shukla, N. D., Schroers-Martin, J., Kathuria, K. R., Sworder, B., Alig, S. K., Frank, M. J., … Alizadeh, A. A. (2022). Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS. BLOOD. AMER SOC HEMATOLOGY. -
Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
Sworder, B., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N. D., Garofalo, A., … Alizadeh, A. A. (2022). Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas. BLOOD. AMER SOC HEMATOLOGY. -
Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
Hosoya, H., Carleton, M., Tanaka, K. L., Sworder, B., Hovanky, V., Duran, G. E., … Kurtz, D. M. (2022). Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA. BLOOD. AMER SOC HEMATOLOGY. -
Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial
Bagot, M., Kim, Y. H., Ortiz-Romero, P. L., Zinzani, P. L., Mehta-Shah, N., Dereure, O., … Porcu, P. (2022). Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial. BLOOD. AMER SOC HEMATOLOGY. -
Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas
Mou, E., Fernandez-Pol, S., Li, S., Kim, Y. H., & Khodadoust, M. S. (2022). Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas. BLOOD. AMER SOC HEMATOLOGY. -
ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas
Song, Y., Ding, N., Yoon, D. H., Reneau, J. C., Wilcox, R. A., Kim, W. S., … Miller, R. A. (2022). ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas. BLOOD. AMER SOC HEMATOLOGY. -
Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors.
Schroers-Martin, J. G., Soo, J., Brisou, G., Scherer, F., Kurtz, D. M., Sworder, B. J., … Alizadeh, A. A. (2023). Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors. Cancer Discovery. -
Correlation of sTNFR2 elevation and disease progression in cutaneous T cell lymphomas
Lee, A., Kim, Y., Khodadoust, M., & Faustman, D. L. (2022). Correlation of sTNFR2 elevation and disease progression in cutaneous T cell lymphomas. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
CYTOF AND SERUM PROTEOMICS SHOW DISTINCT DIFFERENCES IN IMMUNE RESPONSES BETWEEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME TO MONO- AND COMBINATION ANTI-PD-1 IMMUNOTHERAPY
Ramchurren, N., Parks, R., Islas, L., Fling, S., Khodadoust, M., Newell, E., & Glass, D. (2022). CYTOF AND SERUM PROTEOMICS SHOW DISTINCT DIFFERENCES IN IMMUNE RESPONSES BETWEEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME TO MONO- AND COMBINATION ANTI-PD-1 IMMUNOTHERAPY. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
Identification and confirmation via in situ hybridization of Merkel cell polyomavirus in rare cases of posttransplant cutaneous T-cell lymphoma.
Lawrence, L., Wang, A., Charville, G., Liu, C. L., Garofalo, A., Alizadeh, A., … Stehr, H. (2023). Identification and confirmation via in situ hybridization of Merkel cell polyomavirus in rare cases of posttransplant cutaneous T-cell lymphoma. Journal of Cutaneous Pathology. -
Elucidating genetic factors of cutaneous T-cell lymphoma staging and disease severity through machine learning
Schreidah, C. M., Reynolds, G. B., Shen, H., Fahmy, L. M., Choi, J., Duvic, M., … Geskin, L. J. (2023). Elucidating genetic factors of cutaneous T-cell lymphoma staging and disease severity through machine learning. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study
Bagot, M., Kim, Y. H., Ortiz-Romero, P. L., Zinzani, P. L., Beylot-Barry, M., Dalle, S., … Porcu, P. (2023). Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
Genomic abnormalities involving class I HLA are common in advanced cutaneous T-cell lymphoma
Kwang, A., Duran, G., Fernandez-Pol, S., Li, S., Najidh, S., Torres, A. B., … Khodadoust, M. (2023). Genomic abnormalities involving class I HLA are common in advanced cutaneous T-cell lymphoma. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. -
A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis.
Shree, T., Haebe, S. E., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., … Levy, R. (2023). A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis. Blood Advances. -
Specificity of Immunoglobulin High-Throughput Sequencing Minimal Residual Disease Monitoring in Non-Hodgkin Lymphomas.
Shukla, N., Schroers-Martin, J., Sworder, B., Kathuria, K. R., Alig, S., Frank, M. J., … Alizadeh, A. A. (2023). Specificity of Immunoglobulin High-Throughput Sequencing Minimal Residual Disease Monitoring in Non-Hodgkin Lymphomas. Blood Advances. -
Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements.
Wadsworth, P. A., Lawrence, L., Suarez, C. J., Saleem, A., Khodadoust, M. S., Kim, Y. H., … Fernandez-Pol, S. (2023). Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements. Journal of Hematopathology, 16(4), 227–234. -
Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas.
Mou, E., Fernandez-Pol, S., Li, S., Rieger, K. E., Novoa, R., Suarez, C. J., … Khodadoust, M. S. (2024). Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas. American Journal of Hematology. -
A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.
Kastenschmidt, J. M., Schroers-Martin, J. G., Sworder, B. J., Sureshchandra, S., Khodadoust, M. S., Liu, C. L., … Alizadeh, A. A. (2024). A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment. Cell Stem Cell. -
Lacutamab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial
Bagot, M., Kim, Y. H., Geskin, L. J., Ortiz-Romero, P. L., Kim, E., Mehta-Shah, N., … Porcu, P. (2023). Lacutamab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial. BLOOD. AMER SOC HEMATOLOGY. -
Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability
Munayirji, B., Khan, N., Myskowski, P., Geller, S., Noor, S., Kheterpal, M. K., … Moskowitz, A. (2023). Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability. BLOOD. AMER SOC HEMATOLOGY. -
Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma
Schreidah, C. M., DeStephano, D. M., Pan, S. S., Wang, S., Shen, H., Ta, C. N., … Geskin, L. J. (2023). Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring
Sugio, T., Shukla, N., Khodadoust, M. S., Nesselbush, M., Kato, K., Alig, S. K., … Alizadeh, A. A. (2023). An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring. BLOOD. AMER SOC HEMATOLOGY. -
Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)
Gunaratne, R., Zhou, C., Tai, J. W., Schwede, M., Tanaka, K., Alkaitis, M., … Zhang, T. Y. (2023). Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML). BLOOD. AMER SOC HEMATOLOGY. -
Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma.
Glass, D. R., Mayer-Blackwell, K., Ramchurren, N., Parks, K. R., Duran, G. E., Wright, A. K., … Newell, E. W. (2024). Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma. Cell Reports. Medicine, 101527. -
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Horwitz, S. M., Nirmal, A. J., Rahman, J., Xu, R., Drill, E., Galasso, N., … Vardhana, S. A. (2024). Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. Nature Medicine. -
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.
Goyal, A., O'Leary, D., Dabaja, B., Weng, W.-K. K., Zain, J., Cutler, C., … Foss, F. (2024). ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. Transplantation and Cellular Therapy. -
Genetic alteration of class I HLA in cutaneous T-cell lymphoma.
Kwang, A. C., Duran, G. E., Fernandez-Pol, S., Najidh, S., Li, S., Bastidas Torres, A. N., … Khodadoust, M. S. (2024). Genetic alteration of class I HLA in cutaneous T-cell lymphoma. Blood. -
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Horwitz, S. M., Nirmal, A. J., Rahman, J., Xu, R., Drill, E., Galasso, N., … Vardhana, S. A. (2024). Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. Nature Medicine. -
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
Iyer, S. P., Sica, R. A., Ho, P. J., Prica, A., Zain, J., Foss, F. M., … Horwitz, S. M. (2024). Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. The Lancet. Oncology. -
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.
Horwitz, S. M., Feldman, T. A., Ye, J. C., Khodadoust, M. S., Munoz, J., Hamlin, P. A., … Smith, S. M. (2025). Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. Leukemia & Lymphoma, 1–11. -
Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma
Bojanini, L., Herrera, M., Li, S., Bandali, T., Xu, N. Y., Ahmed, A. A., … Kim, Y. H. (2024). Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma. BLOOD. ELSEVIER. -
Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A. N. B., … Mikkilineni, L. (2024). Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma. BLOOD. ELSEVIER. -
Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.
Hosoya, H., Carleton, M., Tanaka, K., Sworder, B., Syal, S., Sahaf, B., … Kurtz, D. M. (2025). Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma. Nature Communications, 16(1), 1824. -
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.
Goyal, A., O'Leary, D., Dabaja, B., Weng, W.-K. K., Zain, J., Cutler, C., … Foss, F. (2025). ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. Journal of the American Academy of Dermatology. -
Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival
Gunaratne, R., Zhou, C., Tai, J. W., Kim, S., Tanaka, K., Rajaram, S., … Zhang, T. Y. (2024). Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival. BLOOD. ELSEVIER. -
Addiction of primary cutaneous ?d T cell lymphomas to JAK/STAT signaling.
Zhang, Y., Yescas, J. A., Tefft, K., Ng, S., Qiu, K., Wang, E. B., … Choi, J. (2025). Addiction of primary cutaneous ?d T cell lymphomas to JAK/STAT signaling. The Journal of Clinical Investigation, 135(8). -
Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma.
Weng, W.-K. K., Iragavarapu, C., Weng, G. M., Hoppe, R. T., Hiniker, S., Khodadoust, M. S., & Kim, Y. H. (2024). Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma. Blood Neoplasia, 1(2), 100007. -
Lacutamab in Patients with Relapsed and/or Refractory Sezary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial
Battistella, M., Gru, A. A., Moins-Teisserenc, H., Bagot, M., Kim, Y.-H. H., Geskin, L. J., … Porcu, P. (2024). Lacutamab in Patients with Relapsed and/or Refractory Sezary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial. BLOOD. ELSEVIER. -
Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial
Bagot, M., Kim, Y. H., Ram-Wolff, C., Dalle, S., Mehta-Shah, N., Huen, A., … Porcu, P. (2024). Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial. BLOOD. ELSEVIER. -
Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
Sugio, T., Nesselbush, M., Shukla, N., Garofalo, A., Mutter, J. A., Esfahani, M. S., … Alizadeh, A. A. (2024). Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas. BLOOD. ELSEVIER. -
Molecular Residual Disease Detection Via Cancer Personalized Profiling By Deep Sequencing in Patients with PTCL Undergoing Autologous Stem Cell Transplantation
Sanghera, C., Ford, J., Gunaratne, R., Chopra, K., Rider, A. B., Sohani, A. R., … Jain, S. (2024). Molecular Residual Disease Detection Via Cancer Personalized Profiling By Deep Sequencing in Patients with PTCL Undergoing Autologous Stem Cell Transplantation. BLOOD. ELSEVIER. -
Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
Zain, J., Iyer, S. P., Marchi, E., Gandhi, M., Kim, Y. H., Khodadoust, M. S., … Horwitz, S. (2024). Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization. BLOOD. ELSEVIER.
-
The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
- Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
- Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
- Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
- TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Practice Locations
Lymphoma Program Palo Alto, CA
Palo Alto, CA
Lymphoma Program
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereLymphoma Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Lymphoma Program in Palo Alto
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(83 reviews)
would highly recommend
Dr Kodadoust is an excellent doctor. I would highly recommend him.
Thank you Stanford Medicine for having such a fine oncologist on your staff
He is an excellent doctor with an excellent team
Excellent doctor and caring
He is an exception doctor
He and his staff are amazing! I feel so lucky to be his patient.
Dr.K and the fellow Alex Salter were great in explaining my issue. They were calm and I didn’t feel rushed.
He is a good doctor.
Best care I have ever had.
Good service with smile
Very informative
Great doctor the by in the world God bless him
Wonderful team. They always treat me very well.
Personal, caring, informed, recommendations vase on facts and your personal situation
He is an amazing doctor.
I have the BEST team of doctors and other care providers. Thank you.
Great doctor and tram
Dr. Kim, Dr. Khodadoust, and team are amazing people. They are always available and ready to help. I feel like they always have a plan and backup plans in place, and are ready for anything. I’ve been with Dr. Kim for several years now, and I’m so glad she is my doctor!
Dr. Khodadoust in Oncology is great
Dr Khodadoust is extraordinary
Dr. Khodadoust, Samantha Kramer PA, and Myra RN are an excellent care team
they are wonderful!
Amazing team
I appreciate him bringing other specialists into my care (Dermatology).
Great "bedside" manner
Dr Khodadoust is the best.
Great Staff!
Dr. Khodadoust, his Physician's Assistant, Sam and Myrna, RN Assistant are the best!
Best care ever!
The CT Lymphoma team is awesome!
Dr Khodadoust. And his staff, Dr.Eckert and Mayra Lozano are wonderful
I am blessed to have such a multi-disciplinary approach team working tirelessly on my behalf. Best place ever for medical expertise and genuine care.!! :-)
I am very grateful and thankful for having the opportunity to have met and have Dr. Youn Kim and Dr. Michael Khodadoust as care providers, who have provided me with excellent care, throughout the past year.
Definitely to recommend to other patients with Lymphoma
Pleasantly Professional! Thorough with complete information. Caring. Detail oriented.
Drs khodaghost & Kim are the best ! and so kind
I enjoy meeting with Dr. Khadadoust. He is very personable and knowledgable.
Met first with Samantha Kramer, NP. She also was very personable, knowledgable and helpful.
All doctors, nurses and medical assistants are outstanding.
Outstanding providers.
Excellent bed side manner as well as his staff
He is the best
There were 2 primary providers. Both were beyond wonderful! Both knowledgeable and both with advanced experience, including great empathy!
Dr. Khodadoust and Dr. Kim are both great!!
I've always had the best best experience!
Dr. Khodadoust was aware my teenage son had an appointment at the same time and made a special point of getting me in and out so I can could join him. Pretty amazing! (Certainly above & beyond).
Dr. Khodadoust's team is wonderful.
Very thorough when checking me. Always explaining everything to me. Very polite.
Excellent.
Would recommend Dr. Khodadoust highly.
With Dr. Khodadoust I know I am in the absolute best care. He explains all of my questions thoroughly and I trust him and his advice 100%. I am so thankful that he is my doctor. Quan Thai is also extremely helpful and responsive. Thank you both!
Drs. Kim & Khodadoust have saved my life.
Everyone is always caring and concerned.
Doctors, nurses and staff are very friendly and courteous.
The attention was very good.
Dr. Khodadoust & his team (Dr. Quan) are very good to me communicating, explaining, plans & treatments.
Dr. Khodadoust and his NP are great.
I have only one appointment to comment on - Dr. Khodadoust was very professional yet understanding, and personable. Everything I was hoping for as I begin this new phase of my life.
Dr. Khodadoust is exceptional!
Dr. Khodadoust is one of the best doctors I have ever worked with.
Dr. Khodadoust seemed more an observer than active participant during this visit. Drs. Kim & Hoppe spoke more to me, then the 3 doctors conversed among themselves. I met Dr. Khodadoust the first time I came to Stanford and I remember him as courteous & gentle.
Very good care providers.
Dr. Khodadoust has a very caring manner.
Dr. Khodadoust is the BEST!
Dr. Khodadoust has a great "bedside manner".
Dr. Michael is a very caring and efficient physician!
Very good.
Dr. Kim and here entire staff are off-the-charts fabulous in every way. Dr. Kim is as brilliant as she is warm. Their care brought tears to my eyes.
Dr. Khodadoust is very responsive, patient and has the ability to explain issues very well.
The best doctor I've ever had!
Very good.
Excellent doctors.
I have been in excellent care throughout my chemo treatments and after - I consider Dr. K had a decent one of your finest doctors dealing with. Lymphoma patients at Stanford Medical - and so very caring and nice -
The doctors were fabulous -
My Dr. "K" was exceptionally kind and concerned in my treatment of lymphoma of the blood cells (non-Hodgkin's) kept me informed - easy to talk to and well liked by me and my family "team" - He is the BEST!!
Dr. Khodadoust was an excellent provider he answered all my questions completely & professionally.
The doctor showed genuine concern, made me feel as is if he was in a hurry, I felt very relaxed with him. He listened, gave me time to ask questions, and his answers were complete and very helpful. We left the initial appointment feeling that my decision to come to Stanford will be turning point in 20+ year history if care.
Dr. Khodadoust has the best bedside manner. He takes as much time as needed to make on comfortable and explains things so I can understand. I can't thank him enough as well as the team for the care they have provided.
I feel blessed to be under Dr. Khodadoust's care! He is beyond wonderful.
Dr. Khodadoust explained my condition & treatment options clearly, thoroughly & in language I could understand.
Dr. K explained my situation as well as the study in layman's terms. I was able to understand & was treated with courtesy & respect.
Dr. Khodadoust has been an outstanding care provider - with sincere concern about my treatment and pain management.
I feel very comfortable and at ease w/Dr. Khodadoust.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records